Renaissance Technologies LLC trimmed its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 36.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 578,800 shares of the biopharmaceutical company's stock after selling 335,300 shares during the quarter. Renaissance Technologies LLC owned approximately 0.29% of Esperion Therapeutics worth $1,273,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in ESPR. Barclays PLC lifted its position in Esperion Therapeutics by 99.6% in the 3rd quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company's stock valued at $510,000 after purchasing an additional 154,509 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company's stock valued at $7,148,000 after purchasing an additional 171,609 shares during the period. Eaton Financial Holdings Company LLC bought a new stake in shares of Esperion Therapeutics during the third quarter valued at approximately $73,000. JPMorgan Chase & Co. grew its holdings in Esperion Therapeutics by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company's stock worth $3,414,000 after buying an additional 19,588 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in Esperion Therapeutics by 96.6% in the 4th quarter. SG Americas Securities LLC now owns 151,482 shares of the biopharmaceutical company's stock worth $333,000 after buying an additional 74,433 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors.
Esperion Therapeutics Stock Performance
Shares of NASDAQ:ESPR opened at $0.96 on Wednesday. The stock has a market capitalization of $190.20 million, a price-to-earnings ratio of -1.50 and a beta of 0.86. Esperion Therapeutics, Inc. has a 1-year low of $0.82 and a 1-year high of $3.94. The company has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.94.
Analyst Ratings Changes
A number of brokerages have issued reports on ESPR. Needham & Company LLC reiterated a "buy" rating and set a $5.00 price target on shares of Esperion Therapeutics in a research report on Friday, April 25th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, April 25th. The Goldman Sachs Group lowered their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $6.42.
Read Our Latest Analysis on Esperion Therapeutics
Esperion Therapeutics Profile
(
Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Further Reading
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
